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Introduction
Nonalcoholic fatty liver disease (NAFLD) includes
steatosis and nonalcoholic steatohepatitis (NASH), which
can be complicated by cirrhosis and hepatocellular car-
cinoma [1]. NAFLD affects over 30 % of the general
population and is associated with type 2 diabetes mellitus
(T2DM), obesity and metabolic syndrome [2, 3]. NAFLD
prevalence in T2DM patients is about 70 % using ultra-
sonography (US) [4]. NAFLD and T2DM share insulin-
resistance, which in the liver increases gluconeogenesis
and glycogenolysis, resulting in hyperglycemia. The
pancreatic beta islet cells adapt to hyperglycemia by
increasing insulin secretion. Hyperinsulinemia up-
regulates several lipogenic transcription factors, pro-
moting hepatic lipid synthesis [5]. The association
between NAFLD and T2DM seems to be the result of a
“common soil” [3]. Several studies showed that NAFLD
predicts T2DM and vice versa, and that each condition
may act as a progression factor for the other [4]. There is
evidence of a high risk of NASH and its progression to
hepatocellular carcinoma in T2DM patients [6]. Con-
versely, recent studies showed that NAFLD not only
predicts diabetes [7], but also contributes to poor gly-
cemic control and chronic complications [8]. Despite its
clear link with T2DM, the association of NAFLD with
family history of diabetes has been poorly investigated. A
recent cross-sectional study in nondiabetic individuals
with NAFLD demonstrated that family history of diabetes
increased the risk of NASH and fibrosis [9].
The aim of this study was to evaluate the prevalence of
NAFLD in healthy first degree relatives of T2DM patients
(T2DM-rel) and in healthy subjects without family history
of T2DM and to assess the risk factors associated with
NAFLD development.
Patients and methods
One hundred twenty-five healthy subjects were enrolled.
A medical history was obtained, and vital and anthro-
pometric parameters were assessed. The exclusion cri-
teria were: known diabetes mellitus, impaired fasting
glucose and dyslipidemia; body mass index (BMI) ≥ 30
kg/m2; alcohol consumption 420 g/d for women and
430 g/d for men; drug abuse; history of liver diseases;
current use of hepatotoxic drugs; psychiatric and neo-
plastic diseases. A 75 g-oral glucose tolerance test
(OGTT) with assessment of fasting and 2-h plasma glu-
cose (2-h PG) was performed. Basal insulinemia, home-
ostasis model assessment index (HOMA index), lipid
profile, renal and liver function markers, and inflamma-
tion indices were assessed.
Ninety four healthy subjects were eligible, 60 T2DM-
rel (37 females, 23 males, median age 35.5 years, range
* Susanna Morano
susanna.morano@uniroma1.it
1 Department of Internal Medicine and Medical Specialties
“Sapienza” University, Viale del Policlinico 155, Rome 00161,
Italy
2 Department of Experimental Medicine, “Sapienza” University,
Viale del Policlinico 155, Rome 00161, Italy
3 Faculty of Economics, UNINT University, via Cristoforo
Colombo 200, Rome 00145, Italy
4 Department of General Surgery “P. Stefanini”, “Sapienza”
University, Viale del Policlinico 155, Rome 00161, Italy
Author's personal copy
22–65) and 34 control subjects without family history of
T2DM (26 females, 8 males, median age 27.5 years,
range 20–60).
After an overnight fasting, all elegible subjects under-
went transabdominal US with a 3.5 MHz convex (Toshiba
Tosbee Tokyo, Japan), performed by two gastro-
enterologists with experience of more than 5000 abdominal
US examinations (41500 scans/year). Presence and
severity of liver steatosis was established according to a
previously published method [10]. After having rehearsed
together several times and after agreement on the modality
to identify the presence and severity of fatty liver, the two
ultrasonographers independently performed US and repor-
ted their results in the standardized form. The interobserver
agreement in detecting presence and severity of fatty liver
was evaluated using the concordance index by kappa sta-
tistics [11]. In case of conflict, the examinations were
reviewed together to provide the best interobserver agree-
ment. The operators were blinded of the laboratory data.
All subjects gave written informed consent. The protocol
was approved by the hospital ethics committee.
Statistical analysis
Continuous variables are expressed as mean± standard
deviation (SD) or median and range. Differences between
groups were evaluated using Wilcoxon rank sum test for
unpaired samples, and by Fisher’s exact test for categorical
variables. The independent variables assessed were: family
history, gender, age, BMI, waist circumference, smoking
habits, physical activity, triglycerides, HDL-cholesterol and
LDL-cholesterol, fasting and 2-h PG at OGTT. The asso-
ciation between steatosis and each variable was assessed
fitting a logistic model after adjustment for gender, age, and
BMI. Values of p o 0.05 were considered significant. All
analyzes were performed with the software R v3.13.
The sample sizes of the two groups allow for a power of
around 0.8 with α= 0.05, when a t-test for unmatched
samples and test for proportions are being considered with
medium effect sizes (e.g., equal to 60 % of the common SD
for the t-test). Analogous power can be provided using
a χ2 test.
Results
None of the subjects had OGTT alterations. T2DM-rel and
control groups were different for age (p= 0.005) and BMI
(p= 0.010). T2DM-rel had higher values of total cholesterol
(p= 0.016) and LDL-cholesterol (p= 0.015), after adjust-
ment for age and BMI, although in the normal range
(Table 1). CRP levels were in the normal range and were
not different between T2DM-rel and control groups.
NAFLD was present in 70 % of T2DM-rel and 47 % of
control subjects. There was an association between presence
of steatosis and T2DM-rel (p= 0.046), not confirmed after
adjustment for age, gender, and BMI (p= 0.118), in the
logistic model.
In T2DM-rel, and not in control subjects, the odds of
having steatosis, after adjustment for age, gender, and BMI,
increased by 6 % for each unit of 2-h PG (mg/dl) (p=
0.027), although in the normal range. No differences were
found in the severity of steatosis and no association was
observed between grades of NAFLD and CRP levels in all
subjects. The agreement between the two ultrasonographers
was almost perfect with a k value of 0.93.
Table 1 Clinical and
biochemical parameters of
T2DM-rel and control subjects
Variable (mean± SD or median range) T2DM-rel Control group p
Age (years) 35.5 (range 22–65) 27.5 (range 20–60) 0.005
BMI (kg/m2) 22.72± 2.38 21.62± 1.77 0.010
Waist (cm) 78.85± 7.89 73.82± 5.47 0.003
FPG (mmol/L) 4.65± 0.49 4.46± 0.30 ns
PPG (mmol/L) 4.88± 1.07 4.35± 0.87 ns
Insulinemia (µU/mL) 11.56± 5.77 13.11± 5.02 ns
HOMA index 2.36± 1.12 2.59± 1.02 ns
Total cholesterol (mmol/L) 4.93± 0.84 4.47± 0.83 0.016
LDL-cholesterol (mmol/L) 2.91± 0.81 2.41± 0.74 0.015
HDL-cholesterol (mmol/L) 1.64± 0.4 1.68± 0.3 ns
Triglycerides (mmol/L) 0.91± 0.32 0.71± 0.29 ns
GPT (UI/L) 17.5± 9.7 13.6± 4.9 ns
Gamma-GT (UI/L) 14.3± 7.7 12.0± 6.0 ns
CRP (μg/L) 1250± 1271 901± 1582 ns
FPG fasting plasma glucose, PPG 2-h plasma glucose at OGTT, GPT glutamic pyruvate transaminase,
CRP C-reactive protein
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Discussion
In this study, a frequent occurrence of steatosis was
observed. Moreover, T2DM-rel showed a higher prevalence
of steatosis, not confirmed after adjustment for age and
BMI. Since T2DM-rel had higher BMI and age, the pre-
valence of NAFLD in this population was not indepen-
dently associated with T2DM family history.
In T2DM-rel the odds of having steatosis increased by
6 % for each unit of 2-h PG, at OGTT, after adjustment for
age and BMI, showing a strong effect of higher values of
2-h PG, although within the normal range. Moreover,
T2DM-rel had a worse lipid profile after adjustment for age
and BMI.
Previous studies demonstrated an increased prevalence
of cardiovascular disease and metabolic syndrome with
increasing fasting plasma glucose levels, both in normo-
glycemic adults and in children/adolescents [12–14].
Elevated 1-h postload plasma glucose levels, in subjects
with normal glucose tolerance, are also predictive of T2DM
and 1-h OGTT glucose ≥ 155 mg/dL is associated with
1.5-fold increased risk of having NAFLD [15, 16]. Elevated
1-h OGTT glucose correlates with an unfavorable inflam-
matory profile, predictor of cardiovascular diseases [17].
Although other studies showed an association between
grades of NAFLD and CRP levels, in this study this cor-
relation was not found [18, 19]. Moreover, 2-h postload
plasma glucose levels, within normal glucose tolerance, and
LDL-cholesterol are associated with carotid intima-media
thickness, a marker of early atherosclerosis [20, 21].
In this view, in the presence of family history of T2DM,
high values of 2-h PG and a worse lipid profile may be not
only predictive of steatosis but also of T2DM and cardio-
vascular disease.
In nondiabetic individuals with NAFLD, family history
of diabetes increases the risk of NASH and fibrosis [9].
Considering the higher risk of steatosis and its progression
to steatohepatitis and fibrosis, it could be appropriate to
search for steatosis in T2DM-rel.
NAFLD worsens glycemic control and contributes to
chronic complications in people with T2DM [8]. Thus,
T2DM-rel with steatosis may have not only a further
increase in the risk of developing T2DM but also a higher
risk of chronic complications.
Given the high prevalence of NAFLD in T2DM-rel and
the higher risk of development of T2DM and its compli-
cations in patients with NAFLD, it could be of importance
to screen this population for NAFLD and for T2DM early,
to provide an appropriate therapy (i.e., lifestyle interven-
tion) to reduce the development of diabetes and liver
complications.
In conclusion, first-degree family history of T2DM is
associated with high prevalence of NAFLD in young
healthy subjects. Moreover, in the same population, there is
a strong effect of 2-h postload plasma glucose levels in the
risk of development of steatosis.
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